Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
Completed
Menarini Group
Phase 2
The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant
(code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.
Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Completed
Menarini Group
Phase 2
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder
characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial
aims at the evaluation of the efficacy and safety of the neurokinin type 2 receptor
antagonist Ibodutant in improving IBS-D symptoms.
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Completed
Menarini Group
Phase 3
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder
characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial
aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as
compared to placebo in women with IBS-D over a 12-week treatment period.
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Terminated
Menarini Group
Phase 3
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder
characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial
aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as
compared to placebo in women with IBS-D over a 24-week treatment period.
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Withdrawn
Menarini Group
Phase 3
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder
characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. The aim of
this trial is the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as
compared to placebo in women with IBS-D over a 12-week treatment period.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
